Please login to the form below

Not currently logged in
Email:
Password:

Ocrevus

This page shows the latest Ocrevus news and features for those working in and with pharma, biotech and healthcare.

Still no breakthrough on Orkambi talks, MPs want answers

Still no breakthrough on Orkambi talks, MPs want answers

As other price deals go through, Orkambi stalled again

Latest news

  • Roche and NHS England hail pricing deal on MS drug Ocrevus Roche and NHS England hail pricing deal on MS drug Ocrevus

    Another pricing deal on high cost medicine. NHS England is claiming another successful negotiation with pharma after it agreed a lower price with Roche for its multiple sclerosis treatment Ocrevus. ... NICE last year recommended Ocrevus for some adults

  • Hemlibra off to a flyer as Roche raises 2019 forecasts Hemlibra off to a flyer as Roche raises 2019 forecasts

    However, new drugs including Ocrevus (ocrelizumab) for multiple sclerosis, cancer immunotherapy Tecentriq (atezolizumab) and new haemophilia drug Hemlibra (emicizumab) acted as a buffer. ... Ocrevus sales came in at CHF 836m in the quarter, up two thirds

  • FDA approves Novartis' next-gen MS drug Mayzent FDA approves Novartis' next-gen MS drug Mayzent

    Analysts predict Mayzent will hit peak sales of up to $3bn, but will have to battle hard with competitors such as Roche's MS star drug Ocrevus.  It is used in ... Mayzent will be priced slightly higher than Ocrevus at $88, 000 per year, but according to

  • Ocrevus helps Roche shrug off biosimilars in 2018 Ocrevus helps Roche shrug off biosimilars in 2018

    Multiple sclerosis therapy Ocrevus (ocrelizumab, pictured above) was once again the star of the show, rising 172% to 2.35bn francs in its first full calendar year on the market, making

  • Novartis: pipeline will generate 60 filings in three years Novartis: pipeline will generate 60 filings in three years

    Following after in MS is ofatumumab, a potential rival to Roche’s fast-growing CD20-targeting drug Ocrevus (ocrelizumab) that is already approved to treat blood cancers under the Arzerra (brand

More from news
Approximately 17 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Webinar: Usability and UX: You’ve been asked to test...What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
...

Infographics